Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal study of pegzilarginase in patients with the rare genetic disease Arginase 1 Deficiency (ARG1-D)

Trial Profile

A pivotal study of pegzilarginase in patients with the rare genetic disease Arginase 1 Deficiency (ARG1-D)

Planning
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2018

At a glance

  • Drugs Pegzilarginase (Primary)
  • Indications Hyperargininaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms PEACE
  • Most Recent Events

    • 11 Dec 2018 According to an Aeglea Bio Therapeutics media release, company expects to dose the first patient in the second quarter of 2019 and expects topline data will be available in the first quarter of 2021.
    • 15 Sep 2018 New trial record
    • 04 Sep 2018 According to an Aeglea Biotherapeutics media release, the company plans to announce the Design of this pivotal study in Q4 2018 and initiate this study in 1H 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top